Zura Bio Limited (ZURA)
NASDAQ: ZURA · Real-Time Price · USD
1.630
+0.040 (2.52%)
Aug 14, 2025, 11:54 AM - Market open
Zura Bio Employees
Zura Bio had 30 employees as of December 31, 2024. The number of employees increased by 15 or 100.00% compared to the previous year.
Employees
30
Change (1Y)
15
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$2,069,933
Market Cap
100.86M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 30 | 15 | 100.00% |
| Dec 31, 2023 | 15 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZURA News
- 27 days ago - Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Zura Bio Announces Chief Financial Officer Transition - Business Wire
- 2 months ago - Zura Bio to Present at the Jefferies Global Healthcare Conference - Business Wire
- 3 months ago - Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa - Business Wire
- 3 months ago - Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates - Business Wire
- 5 months ago - Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates - Business Wire
- 6 months ago - Zura Bio to Present at the Leerink Partners Global Healthcare Conference - Business Wire
- 8 months ago - Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis - Business Wire